All News about Biovaxys Technology Corp
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://www.financialnewsmedia.com/wp-content/uploads/2022/10/BIOV-1.jpg)
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Topics
Death
Exposures
Death
![](https://www.financialnewsmedia.com/wp-content/uploads/2020/12/BIOV.small_.jpg)
Topics
Intellectual Property
Exposures
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Topics
Economy
Exposures
Supply Chain
![](https://www.issuerdirect.com/images/AW-ISDR-ICON.png)
From The Market Herald
Via AccessWire
Exposures
COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
Exposures
COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Exposures
COVID-19
Exposures
COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Topics
Death
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
Exposures
COVID-19
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021
Topics
Intellectual Property
Exposures
Intellectual Property
Exposures
COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
Exposures
COVID-19
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
September 28, 2021
Exposures
COVID-19
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
September 28, 2021
Exposures
COVID-19
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
September 28, 2021
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
September 23, 2021
Exposures
COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.